{
    "id": "dbpedia_780_1",
    "rank": 55,
    "data": {
        "url": "https://digitalcommons.providence.org/chiles-pubs/",
        "read_more_link": "",
        "language": "en",
        "title": "Earle A. Chiles Research Institute Publications",
        "top_image": "",
        "meta_img": "",
        "images": [
            "https://digitalcommons.providence.org/assets/md5images/8e240588cf8cd3a028768d4294acd7d3.png",
            "https://digitalcommons.providence.org/assets/md5images/5d9836aff47ecd7e9c5bbdfeb18bfd3a.gif",
            "https://digitalcommons.providence.org/assets/md5images/4e1a49f425c65556e9c330e220f97270.png",
            "https://digitalcommons.providence.org/assets/md5images/eb9861a0b1f9f72f63d2117b9f4fb8c1.gif",
            "https://digitalcommons.providence.org/assets/md5images/317f2e4a3f20ebc744f8f1f6bfac9626.gif",
            "https://digitalcommons.providence.org/assets/md5images/1ed63fdeb615258b0f9612f0fec0b3ae.gif",
            "https://digitalcommons.providence.org/assets/md5images/c75ea421c99eff3f00d224f877601cb6.gif"
        ],
        "movies": [],
        "keywords": [],
        "meta_keywords": [
            ""
        ],
        "tags": null,
        "authors": [],
        "publish_date": null,
        "summary": "",
        "meta_description": "",
        "meta_lang": "en",
        "meta_favicon": "/favicon.ico",
        "meta_site_name": "",
        "canonical_link": null,
        "text": "Follow\n\nindex\n\nSubmissions from 2024 2024\n\nLink\n\nRadiation Therapy With or Without Cisplatin for Local Recurrences of Endometrial Cancer: Results From an NRG Oncology/GOG Prospective Randomized Multicenter Clinical Trial., Ann H Klopp, Danielle Enserro, Matthew Powell, Marcus Randall, Julian C Schink, Robert S Mannel, Laura Holman, David Bender, Christina L Kushnir, Floor Backes, Susan L Zweizig, Steven Waggoner, Kristin A Bradley, Lana DeSouza Lawrence, Parviz Hanjani, Christopher J Darus, William Small, Higinia R Cardenes, Jonathan M Feddock, and David S Miller\n\nLink\n\nCITEViz: interactively classify cell populations in CITE-Seq via a flow cytometry-like gating workflow using R-Shiny., Garth L Kong, Thai T Nguyen, Wesley K Rosales, Anjali D Panikar, John H W Cheney, Theresa A Lusardi, William M Yashar, Brittany M Curtiss, Sarah A Carratt, Theodore P Braun, and Julia E Maxson\n\nLink\n\nFluorescence tracking demonstrates T cell recirculation is transiently impaired by radiation therapy to the tumor., Gwen Kramer, Tiffany Blair, Shelly Bambina, Aanchal Preet Kaur, Alejandro F Alice, Jason R Baird, David Friedman, Alexa K Dowdell, Michio Tomura, Clemens Grassberger, Brian D. Piening, Marka R Crittenden, and Michael J. Gough\n\nLink\n\nA call to adapt the regulation of HLA testing for T cell receptor-based therapeutics., Miriam Meyer, Andrea Mahr, Joanna Brewer, Volker Daniel, Justine Dell'Aringa, Tony Goldstone, Sarah Hersey, Ian Johnston, Pamela Larson, Michael Loveridge, Gavin MacBeath, Mark Moyer, Dirk Nagorsen, Sophie Papa, Leanne Peiser, Koustubh Ranade, Ruben Rizzi, Axel Roers, Dolores Schendel, Pallavur Sivakumar, Eric Tran, Özlem Türeci, Luise Weigand, Anders Wennborg, Dennis Williams, Cassian Yee, and Cedrik M Britten\n\nLink\n\nIntegrative multi-omics profiling in human decedents receiving pig heart xenografts., Eloi Schmauch, Brian Piening, Maedeh Mohebnasab, Bo Xia, Chenchen Zhu, Jeffrey Stern, Weimin Zhang, Alexa K Dowdell, Jacqueline I Kim, David Andrijevic, Karen Khalil, Ian S Jaffe, Bao-Li Loza, Loren Gragert, Brendan R Camellato, Michelli F Oliveira, Darragh P O'Brien, Han M Chen, Elaina Weldon, Hui Gao, Divya Gandla, Andrew Chang, Riyana Bhatt, Sarah Gao, Xiangping Lin, Kriyana P Reddy, Larisa Kagermazova, Alawi H Habara, Sophie Widawsky, Feng-Xia Liang, Joseph Sall, Alexandre Loupy, Adriana Heguy, Sarah E B Taylor, Yinan Zhu, Basil Michael, Lihua Jiang, Ruiqi Jian, Anita S Chong, Robert L Fairchild, Suvi Linna-Kuosmanen, Minna U Kaikkonen, Vasishta Tatapudi, Marc Lorber, David Ayares, Massimo Mangiola, Navneet Narula, Nader Moazami, Harvey Pass, Ramin S Herati, Adam Griesemer, Manolis Kellis, Michael P Snyder, Robert A Montgomery, Jef D Boeke, and Brendan J Keating\n\nLink\n\nFinal outcomes analysis of the cell product SQZ-PBMC-HPV Phase 1 trial in incurable HPV16+ solid tumors shows improved overall survival in patients with increased CD8+ T cell tumor infiltration., Alice N Weaver, Wade T Iams, Jong Chul Park, Monica Mita, Udo Holtick, Michael S Gordon, Kerry J Rodabaugh, Neesha Dhani, Prakash Neupane, Matthew Taylor, E Amanda Duvall, Julia Jennings, Nathan R Miselis, Scott Loughhead, Marshelle S Warren, Howard Bernstein, Jens P Klussmann, Joaquina Baranda, and Antonio Jimeno\n\nLink\n\nA whole-slide foundation model for digital pathology from real-world data., Hanwen Xu, Naoto Usuyama, Jaspreet Bagga, Sheng Zhang, Rajesh Rao, Tristan Naumann, Cliff Wong, Zelalem Gero, Javier González, Yu Gu, Yanbo Xu, Mu Wei, Wenhui Wang, Shuming Ma, Furu Wei, Jianwei Yang, Chunyuan Li, Jianfeng Gao, Jaylen Rosemon, Tucker Bower, Soohee Lee, Roshanthi Weerasinghe, Bill J Wright, Ari Robicsek, Brian Piening, Carlo Bifulco, Sheng Wang, and Hoifung Poon\n\nSubmissions from 2023 2023\n\nLink\n\nA Rare Case of Demodicosis Following Treatment With Oral Fluconazole., Joshua A Bezecny, Emily Bolton, Matthew H Taylor, and Elizabeth G Berry\n\nLink\n\nCT275 / 15 - Phase 1 clinical update of allogeneic invariant natural killer T cells (iNKTs), agenT-797, alone or in combination with pembrolizumab or nivolumab in patients with advanced solid tumors, B Carneiro\n\nLink\n\nCT275 / 15 - Phase 1 clinical update of allogeneic invariant natural killer T cells (iNKTs), agenT-797, alone or in combination with pembrolizumab or nivolumab in patients with advanced solid tumors, B Carneiro, Rachel E Sanborn, and See full list of authors in comments\n\nLink\n\nAbstract CT123: Trial in progress: First-in-human immunotherapy-trio for advanced head and neck squamous cell carcinoma, MA Couey, Matthew H Taylor, William L. Redmond, Brady Bernard, Richard Bryan Bell, Carlo Bifulco, Brian D. Piening, Walter Urba, Bernard A Fox, and Rom Leidner\n\nLink\n\nTemporary Knockdown of p53 During Focal Limb Irradiation Increases the Development of Sarcomas., Andrea R Daniel, Chang Su, Nerissa T Williams, Zhiguo Li, Jianguo Huang, Omar Lopez, Lixia Luo, Yan Ma, Lorraine da Silva Campos, Sara R Selitsky, Jennifer L Modliszewski, Siyao Liu, Rosa Hernansaiz-Ballesteros, Yvonne M Mowery, Diana M Cardona, Chang-Lung Lee, and David G Kirsch\n\nLink\n\nPractical considerations when providing palliative care to patients with neuroendocrine tumors in the context of routine disease management or hospice care., Jaydira Del Rivero, Josh Mailman, Michael W Rabow, Jennifer A Chan, Sarah Creed, Hagen F Kennecke, Janice Pasieka, Jennifer Zuar, Simron Singh, and Lauren Fishbein\n\nLink\n\nCancer's Dark Matter: Lighting the Abyss Unveils Universe of New Therapies., Bernard A Fox, Walter J Urba, Shawn M Jensen, David B Page, Brendan D Curti, Rachel E Sanborn, and Rom S Leidner\n\n13. Long-term efficacy, safety and predictors of response to amivantamab among patients with post-platinum EGFR exon 20 insert (Ex20ins)-mutated advanced non-small cell lung cancer (aNSCLC) — CHRYSALIS (NCT02609776), P Garrido, Rachel E Sanborn, and See full list of authors in comments\n\nLink\n\nHN-CLEAR: Head and Neck Consensus Language for Ease and Reproducibility, a Multidisciplinary Consensus Mechanism for Head and Neck Pathology., Ruta Gupta, Munita Bal, Justin A Bishop, Keith D Hunter, Kelly Magliocca, Raja R Seethala, Lester D R Thompson, Ilan Weinreb, Peter Angelos, Beth Beadle, R Bryan Bell, Jonathan R Clark, Robert Ferris, Shao Hui Huang, D Neil Hayes, Rahul Ladwa, Jean Yang, Nicole A Cipriani, Brenda L Nelson, Peter M Sadow, and James S Lewis\n\nLink\n\nThe role of dendritic cells in radiation-induced immune responses., Aanchal Preet Kaur, Alejandro F Alice, Marka R Crittenden, and Michael J. Gough\n\nLink\n\nAbstract 6410: Deciphering the role of MyD88 signaling pathway in regulating type I IFN-mediated responses to radiation therapy in solid tumors, Aanchal Preet Kaur, Terry R. Medler, Tiffany C. Blair, Alejandro F. Alice, Megan R. Ball, Alexa K Dowdell, Brian D. Piening, Marka R Crittenden, and Michael J. Gough\n\n3D co-culture models demonstrate radiation-mediated activation of tumor-associated macrophages, AP Kaur, Marka R Crittenden, Michael J. Gough, and See all authors in comments\n\nLink\n\nSALVO: Single Arm Trial of Ipilimumab and Nivolumab as Adjuvant Therapy for Resected Mucosal Melanoma., Lisa A Kottschade, Gregory Russell Pond, Anthony J Olszanski, Yousef Zakharia, Evidio Domingo-Musibay, Ralph J Hauke, Brendan Curti, Sarah Schober, Mohammed M Milhem, Matthew S Block, Tina Hieken, and Robert R McWilliams\n\nLink\n\nAn Analysis of Patient Characteristics Associated with Myelosuppression Among Small Cell Lung Cancer (SCLC) Patients Treated in US Community Cancer Care Practices, L Lopez-Gonzalez, Rachel E Sanborn, Roshanthi Weerasinghe, Amy S. Parrish, and See full list of authors in comments\n\nLong-term efficacy, safety, and predictors of response to amivantamab among patients with post-platinum EGFR Ex20ins-mutated advanced NSCLC, PG Lopez, Rachel E Sanborn, and See full list of authors in comments\n\nLink\n\nLorigerlimab, a bispecific PD-1×CTLA-4 DART molecule in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): A phase 1 expansion (exp) cohort., Jason J. Luke, Rachel E Sanborn, and See full list of authors in comments\n\nLink\n\nCT251 / 14 - Phase 1/2 study of HST-1011, an oral CBL-B inhibitor, alone and in combination with anti-PD1 in patients with advanced solid tumors, J Luke, Rachel E Sanborn, and See full list of authors in comments\n\nLink\n\nMyeloid MyD88 restricts CD8, Terry R Medler, Tiffany C Blair, Alejandro F Alice, Alexa K Dowdell, Brian D Piening, Marka R Crittenden, and Michael J Gough\n\nLink\n\nTumor resident memory CD8 T cells and concomitant tumor immunity develop independently of CD4 help., Terry R Medler, Gwen Kramer, Shelly Bambina, Andrew J Gunderson, Alejandro Alice, Tiffany Blair, Lauren Zebertavage, Thomas Duhen, Rebekka Duhen, Kristina Young, Marka R Crittenden, and Michael J Gough\n\nAbstract CT226: Crizotinib (C) in patients (pts) with solid tumors with MET amplification (amp) or mutation (mut): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study, Kathryn F. Mileham, Rom Leidner, and See full list of authors in comments\n\nLink\n\nMulticenter International Study of the Consensus Immunoscore for the Prediction of Relapse and Survival in Early-Stage Colon Cancer., Bernhard Mlecnik, Alessandro Lugli, Gabriela Bindea, Florence Marliot, Carlo Bifulco, Jiun-Kae Jack Lee, Inti Zlobec, Tilman T Rau, Martin D Berger, Iris D Nagtegaal, Elisa Vink-Börger, Arndt Hartmann, Carol I Geppert, Julie Kolwelter, Susanne Merkel, Robert Grützmann, Marc Van den Eynde, Anne Jouret-Mourin, Alex Kartheuser, Daniel Léonard, Christophe Remue, Julia Wang, Prashant Bavi, Michael H A Roehrl, Pamela S Ohashi, Linh T Nguyen, SeongJun Han, Heather L MacGregor, Sara Hafezi-Bakhtiari, Bradly G Wouters, Giuseppe V Masucci, Emilia K Andersson, Eva Zavadova, Michal Vocka, Jan Spacek, Lubos Petruzelka, Bohuslav Konopasek, Pavel Dundr, Helena Skalova, Kristyna Nemejcova, Gerardo Botti, Fabiana Tatangelo, Paolo Delrio, Gennaro Ciliberto, Michele Maio, Luigi Laghi, Fabio Grizzi, Tessa Fredriksen, Bénédicte Buttard, Lucie Lafontaine, Pauline Maby, Amine Majdi, Assia Hijazi, Carine El Sissy, Amos Kirilovsky, Anne Berger, Christine Lagorce, Christopher Paustian, Carmen Ballesteros-Merino, Jeroen Dijkstra, Carlijn van de Water, Shannon van Lent-van Vliet, Nikki Knijn, Ana-Maria Mușină, Dragos-Viorel Scripcariu, Boryana Popivanova, Mingli Xu, Tomonobu Fujita, Shoichi Hazama, Nobuaki Suzuki, Hiroaki Nagano, Kiyotaka Okuno, Toshihiko Torigoe, Noriyuki Sato, Tomohisa Furuhata, Ichiro Takemasa, Prabhu Patel, Hemangini H Vora, Birva Shah, Jayendrakumar B Patel, Kruti N Rajvik, Shashank J Pandya, Shilin N Shukla, Yili Wang, Guanjun Zhang, Yutaka Kawakami, Francesco M Marincola, Paolo A Ascierto, Bernard A Fox, Franck Pagès, and Jérôme Galon\n\nNovel Directions of ADCs in Breast Cancer. Binaytara Foundation Highlights from SABCS 2022; 2023 January 20; Seattle, WA., David B Page\n\nLink\n\nMulti-institutional validation of a radiomics-based artificial intelligence method for predicting response to PD-1/PD-L1 immune checkpoint inhibitor (ICI) therapy in stage IV NSCLC, RB Parikh, Brendan Curti, and See full list of authors in comments\n\nLink\n\nScreening for occult cancer after unprovoked venous thromboembolism: Assessing the current literature and future directions., Sarah S Patel, Derrick Tao, Hannah S McMurry, and Joseph J Shatzel\n\nLink\n\nAbstract 6764: Multi-parametric comparison of scRNA-seq with CITE-seq and ultrahigh-plex spatial phenotyping of proteins in FFPE head and neck tumor biopsies: An opportunity to generate uniquely comprehensive multi-omic single cell datasets to investigate the tumor microenvironment, Aditya Pratapa, Brady Bernard, Brian D. Piening, Rom Leidner, Bernard A Fox, and See all authors in comments\n\nLink\n\nToward structuring real-world data: Deep learning for extracting oncology information from clinical text with patient-level supervision., Sam Preston, Mu Wei, Rajesh Rao, Robert Tinn, Naoto Usuyama, Michael Lucas, Yu Gu, Roshanthi Weerasinghe, Soohee Lee, Brian D. Piening, Paul Tittel, Naveen Valluri, Tristan Naumann, Carlo Bifulco, and Hoifung Poon\n\nLink\n\nChallenges and opportunities in the development of combination immunotherapy with OX40 agonists., William L Redmond\n\nLink\n\nAbstract CT133: Trial in progress: a multicenter phase 1/1b dose escalation study of WTX-124 as a monotherapy and in combination with pembrolizumab in patients with selected advanced or metastatic solid tumors, I Rodriquez-Rivera, Brendan Curti, and See full list of authors in comments\n\nLink\n\n2166 / 8 - Analysis of ctDNA next generation sequencing (NGS) for predicting response to amivantamab and lazertinib among patients with EGFR-mutant NSCLC after progression on osimertinib and platinum-based chemotherapy (CHRYSALIS-2 Cohort A), Rachel E Sanborn and See full list of authors in comments\n\nLink\n\nThe immunogenic radiation and new players in immunotherapy and targeted therapy for head and neck cancer., Shay Sharon, Narmeen Daher-Ghanem, Deema Zaid, Michael J Gough, and Nataly Kravchenko-Balasha\n\nLink\n\nA phase Ib study of interleukin-2 plus pembrolizumab for patients with advanced melanoma., Ann W Silk, Brendan Curti, Jennifer Bryan, Tracie Saunders, Weichung Shih, Michael P Kane, Phoebe Hannon, Christopher B Fountain, Jessica Felcher, Andrew Zloza, Howard L Kaufman, Janice M Mehnert, and David F McDermott\n\nLink\n\nDevelopments in Checkpoint Inhibitor Therapy for the Management of Deficient Mismatch Repair (dMMR) Rectal Cancer., Alan Su, Rodrigo Pedraza, and Hagen F Kennecke\n\nT Cell Agonists. SITC Winter School Annual Meeting; 2023 January 18; Austin, TX., Andrew D Weinberg\n\nLink\n\nDisruption of the MYC Super-Enhancer Complex by Dual Targeting of FLT3 and LSD1 in Acute Myeloid Leukemia., William M Yashar, Brittany M Curtiss, Daniel J Coleman, Jake VanCampen, Garth Kong, Jommel Macaraeg, Joseph Estabrook, Emek Demir, Nicola Long, Daniel Bottomly, Shannon K McWeeney, Jeffrey W Tyner, Brian J Druker, Julia E Maxson, and Theodore P Braun\n\nSubmissions from 2022 2022\n\nLink\n\nA phase 1 multiple-ascending dose study to evaluate the safety and tolerability of XmAb23104 (PD-1 x ICOS) in subjects with selected advanced solid tumors (DUET-3)., Mehmet Akce, Rom Leidner, and See full list of authors in comments\n\nLink\n\nEnhancement of anti-tumor efficacy of immune checkpoint blockade by alpha-tocopheryloxacetic acid-lysine, Emmanuel Akporiaye, William L. Redmond, and Melissa Kasiewicz\n\n940 siRNA screen of upregulated genes identifies targets for a multiantigen polyepitope vaccine to prevent HNSCC, Fnu Alka, James Annis, Brady Bernard, and Sasha Stanton\n\nLink\n\nGut microbiota analyses of Saudi populations for type 2 diabetes-related phenotypes reveals significant association., Fahad A Al-Muhanna, Alexa K Dowdell, Abdulmohsen H Al Eleq, Waleed I Albaker, Andrew W Brooks, Ali I Al-Sultan, Abdullah M Al-Rubaish, Khaled R Alkharsah, Raed M Sulaiman, Abdulaziz A Al-Quorain, Cyril Cyrus, Rudaynah A Alali, Chittibabu Vatte, Fred L Robinson, Xin Zhou, Michael P Snyder, Afnan F Almuhanna, Brendan J Keating, Brian D. Piening, and Amein K Al-Ali\n\nLink\n\nPerspectives in Melanoma: meeting report from the Melanoma Bridge (December 2nd - 4th, 2021, Italy)., Paolo A Ascierto, Sanjiv S Agarwala, Christian Blank, Corrado Caracò, Richard D Carvajal, Marc S Ernstoff, Soldano Ferrone, Bernard A Fox, Thomas F Gajewski, Claus Garbe, Jean-Jacques Grob, Omid Hamid, Michelle Krogsgaard, Roger S Lo, Amanda W Lund, Gabriele Madonna, Olivier Michielin, Bart Neyns, Iman Osman, Solange Peters, Poulikos I Poulikakos, Sergio A Quezada, Bradley Reinfeld, Laurence Zitvogel, Igor Puzanov, and Magdalena Thurin\n\nLink\n\nPerspectives in Immunotherapy: meeting report from the Immunotherapy Bridge, December 1st-2nd, 2021., Paolo A Ascierto, Antonio Avallone, Nina Bhardwaj, Carlo Bifulco, Sergio Bracarda, Joshua D Brody, Luigi Buonaguro, Sandra Demaria, Leisha A Emens, Robert L Ferris, Jérôme Galon, Samir N Khleif, Christopher A Klebanoff, Tamara Laskowski, Ignacio Melero, Chrystal M Paulos, Sandro Pignata, Marco Ruella, Inge Marie Svane, Janis M Taube, Bernard A Fox, Patrick Hwu, and Igor Puzanov\n\nLink\n\nThe \"Great Debate\" at Immunotherapy Bridge 2021, December 1st-2nd, 2021., Paolo A Ascierto, Lisa H Butterfield, Olivera J Finn, Andrew Futreal, Omid Hamid, Theresa LaVallee, Michael A Postow, Igor Puzanov, Jeffrey Sosman, Bernard A Fox, and Patrick Hwu\n\nClinical actionability and therapy selection for advanced NSCLC patients tested using comprehensive genomic profiling, B Bapat, R Weerasignhe, R Meng, A Dowdell, SC Chang, B Schroeder, C Bifulco, and B Piening\n\nEnhancing clinical genomics datasets with multimodal EHR data and imaging, Carlo Bifulco\n\nLightning talks: AI in healthcare, Carlo Bifulco\n\nSpatial Biology: a Cambrian Explosion of Technology, Carlo Bifulco\n\nThe virtual molecular tumor board as a tool for integrating omics in the delivery of precision oncology, Carlo Bifulco\n\nLink\n\nA Random Forest Genomic Classifier for Tumor Agnostic Prediction of Response to Anti-PD1 Immunotherapy., Emma Bigelow, Suchi Saria, Brian D. Piening, Brendan Curti, Alexa K Dowdell, Roshanthi Weerasinghe, Carlo Bifulco, Walter Urba, Noam Finkelstein, Elana J Fertig, Alex Baras, Neeha Zaidi, Elizabeth Jaffee, and Mark Yarchoan\n\nFluorescence tagging to monitor CD8 T cell recirculation from the tumor to the tumor-draining lymph node: the impact of focal radiation therapy on recirculation, TC Blair, Brian D. Piening, Marka R Crittenden, Michael J. Gough, and See full list of authors in comments\n\nLink\n\nICOS is upregulated on T cells following radiation and agonism combined with radiation results in enhanced tumor control., Tiffany Blair, Jason Baird, Shelly Bambina, Gwen Kramer, Monica Gostissa, Christopher J Harvey, Michael J Gough, and Marka R Crittenden\n\nLink\n\nFluorescent tracking identifies key migratory dendritic cells in the lymph node after radiotherapy., Tiffany Blair, Shelly Bambina, Gwen Kramer, Alexa K Dowdell, Alejandro F Alice, Jason R Baird, Amanda W Lund, Brian D. Piening, Marka R Crittenden, and Michael J. Gough\n\nLink\n\nPraluzatamab ravtansine, a CD166-targeting antibody-drug conjugate, in patients with advanced solid tumors: an open-label phase 1/2 trial., Valentina Boni, Mary J Fidler, Hendrik-Tobias Arkenau, Alexander Spira, Funda Meric-Bernstam, Nataliya Uboha, Rachel E Sanborn, Randy F Sweis, Patricia LoRusso, Misako Nagasaka, Javier Garcia-Corbacho, Shadia Jalal, James J Harding, Stella K Kim, Iris H C Miedema, Danielle J Vugts, Marc C Huisman, Gerben J C Zwezerijnen, Guus A M S van Dongen, Catharina W Menke-van der Houven van Oordt, Song Wang, Tam Dang, Ivan A Zein, Olga Vasiljeva, Susan K Lyman, Virginia Paton, Alison Hannah, and Joyce F Liu\n\n997 T cell immunotherapies trigger neutrophils to eliminates heterogenous tumors, Sadna Budha, Rebekka Duhen, Andrew Weinberg, and See all authors in comments\n\nLink\n\nChanges in T-cell subsets and clonal repertoire during chemoimmunotherapy with pembrolizumab and paclitaxel or capecitabine for metastatic triple-negative breast cancer., Brie Chun, Joanna Pucilowska, Shu-Ching Chang, Isaac Kim, Benjamin Nikitin, Yoshinobu Koguchi, William L. Redmond, Brady Bernard, Venkatesh Rajamanickam, Nathan Polaske, Paul A Fields, Valerie Conrad, Mark Schmidt, Walter Urba, Alison Conlin, Heather L McArthur, and David B Page\n\nLink\n\nCT243 / 4 - Phase 1 study of TAK-676 + pembrolizumab following radiation therapy in patients with advanced non-small-cell lung cancer (NSCLC), triple-negative breast cancer (TNBC), or squamous-cell carcinoma of the head and neck (SCCHN), Benjamin Cooper, David B Page, and See full list of authors in comments\n\nLink\n\nFor Ethical Fundraising from Patients, Respect them as Partners., Brendan Curti\n\nLink\n\nChapter 72: Cancer of the Skin, Brendan Curti, Sancy Leachman, and Walter Urba\n\nLink\n\nDose escalation of davoceticept, a conditional CD28 costimulator and dual checkpoint inhibitor, in advanced malignancies (NEON-1), Diwakar Davar, Rachel E Sanborn, and See full list of authors in comments\n\nPhase 1 study of SEA-TGT, a human, nonfucosylated monoclonal antibody directed to TIGIT with enhanced immune effector function, in patients with advanced malignancies (SGNTGT-001, trial in progress), D Davar, Rachel E Sanborn, and See full list of authors in comments\n\n546 A phase I dose escalation study of STEMVAC, a multi-antigen, multi-epitope Th1 selective plasmid-based vaccine, targeting stem cell associated proteins in patients with advanced breast cancer, Mary Disis, Sasha Stanton, and See all authors in comments\n\nLink\n\nAutomatic Patient Matching for Genome-Guided Adoptive Cell Immunotherapy Trials at a Large Health System, Alexa K Dowdell, Tucker Bower, Benjamin Cosgrove, Roshanthi Weerasinghe, Ann Vita, Brian D. Piening, Carlo Bifulco, Eric Tran, and Rom Leidner\n\nLink\n\nOX40 agonist stimulation increases and sustains humoral and cell-mediated responses to SARS-CoV-2 protein and saRNA vaccines., Rebekka Duhen, Michael Beymer, Shawn M. Jensen, Srinivas Abbina, Suraj Abraham, Nikita Jain, Anitha Thomas, Andrew J Geall, Hong-Ming Hu, Bernard A Fox, and Andrew D Weinberg\n\nLink\n\nPD-1 and ICOS co-expression identifies tumor-reactive CD4 T cells in human solid tumors., Rebekka Duhen, Olivier Fesneau, Kimberly Samson, Alexandra K Frye, Michael Beymer, Venkatesh Rajamanickam, David Ross, Eric Tran, Brady Bernard, Andrew D Weinberg, and Thomas Duhen\n\nOX40 boosts and sustains humoral and cellular immune responses to SARS-CoV-2 spike protein and RNA vaccinations, R Duhen, Bernard A Fox, Andrew D Weinberg, and See all authors in comments\n\nPD-1 and ICOS co-expression identifies tumor-reactive CD4 T cells in human solid tumors, Thomas Duhen\n\nLink\n\nReal-world burden of chemotherapy-induced myelosuppression in patients with small cell lung cancer: a retrospective analysis of electronic medical data from community cancer care providers., Robert S. Epstein, Roshanthi Weerasinghe, Amy S. Parrish, JoAnn Krenitsky, Rachel E Sanborn, and Tehseen Salimi\n\nLink\n\nT Cells Engineered to Express Immunoreceptors Targeting the Frequently Expressed Medullary Thyroid Cancer Antigens Calcitonin, CEA, and RET M918T., Timothy A Erickson, Yi-Ping Shih, Joseph Fass, Myungkyu Jang, and Eric Tran\n\nLink\n\nA Phase II, Single-arm Trial of Sunitinib and Erlotinib in Advanced Renal Cell Carcinoma., Zizhen Feng, Brendan Curti, David I Quinn, John M Strother, Zunqiu Chen, Rebecca Agnor, Tomasz M Beer, and Christopher W Ryan\n\nLink\n\nPhase II Randomized Trial of Transoral Surgery and Low-Dose Intensity Modulated Radiation Therapy in Resectable p16+ Locally Advanced Oropharynx Cancer: An ECOG-ACRIN Cancer Research Group Trial (E3311)., Robert L Ferris, Yael Flamand, Gregory S Weinstein, Shuli Li, Harry Quon, Ranee Mehra, Joaquin J Garcia, Christine H Chung, Maura L Gillison, Umamaheswar Duvvuri, Bert W O'Malley, Enver Ozer, Giovana R Thomas, Wayne M Koch, Neil D Gross, Richard Bryan Bell, Nabil F Saba, Miriam Lango, Eduardo Méndez, and Barbara Burtness\n\nIdentification of a subset of tumor-reactive CD8 TIL expressing NKG2A in HNSCC and CRC, O Fesneau, K Samson, V Rajamanickam, D Ross, and Thomas Duhen\n\nA Vision to Cure More Patients with Cancer by Better Identifying the Impact of Treatment and Modifying Therapy Appropriately, Bernard Fox\n\nCombining 10x scRNA-seq and 100 plex mIF: Too much data or complimentary technologies to examine what works, Bernard Fox\n\nProgress in Cellular Immunotherapy - It is not Just Mutations: A Vision into Combinations to Expect in 2023 and Beyond, Bernard Fox\n\nEvaluation of long-term anti-Spike immune response following a novel coronavirus vaccine (CORVax): electroporation of SARS-CoV-2 Spike plasmid DNA plus plasmid IL-12, Bernard A Fox\n\nLink\n\nRecommended phase 2 dose (RP2D) of HB-200 arenavirus-based cancer immunotherapies in patients with HPV16+ cancers., Siqing Fu, Rom Leidner, and Matthew H Taylor\n\nLink\n\nA phase 2 study of an off-the-shelf, multi-neoantigen vector (ADXS-503) in patients with metastatic non–small cell lung cancer either progressing on prior pembrolizumab or in the first-line setting., Gregory James Gerstner, Rachel E Sanborn, and See full list of authors in comments\n\nLink\n\nA phase 1b, multicenter, dose-escalation study of subasumstat (TAK-981) in combination with pembrolizumab in patients (pts) with advanced solid tumors., Sanjay Goel, Rachel E Sanborn, and See full list of authors in comments\n\nLink\n\nSafety and tolerability of MEDI0562, an OX40 agonist monoclonal antibody, in combination with durvalumab or tremelimumab in adult patients with advanced solid tumors., Jonathan W Goldman, Sarina A Piha-Paul, Brendan Curti, Katrina S Pedersen, Todd M Bauer, Stefanie L Groenland, Richard D Carvajal, Vaishali Chhaya, Gray Kirby, Kelly McGlinchey, Scott A Hammond, Katie L Streicher, Danielle Townsley, Young Kwang Chae, Jens Voortman, Aurelien Marabelle, and John Powderly\n\nFluorescence tagging to monitor CD8 T cell recirculation from the tumor to the tumor-draining lymph node: the impact of focal radiation therapy on recirculation, Michael J. Gough\n\nTumor resident memory CD8 T cell formation and concomitant tumor immunity is CD40L dependent and CD4 independent, Michael J. Gough\n\nLink\n\nThe paradox of radiation and T cells in tumors., Michael J. Gough and Marka R Crittenden\n\nDurability of B and T cell responses against a spike protein of SARS-CoV2 elicited by mRNA vaccines, LT Hamilton, Bernard A Fox, William L. Redmond, Brian D. Piening, and See full list of authors in comments\n\nLink\n\n5 Development of a vaccine to intercept oral cancer, Traci Hilton, Tarsem Moudgil, Richard Bryan Bell, and See all authors in comments\n\nLink\n\n731 A first-in-human trial of an integrin beta-6 targeted antibody-drug conjugate (ADC), SGN-B6A, in patients with advanced solid tumors: interim results of a phase 1 study (SGNB6A-001), Antoine Hollebecque, Rachel E Sanborn, and See full list of authors in comments\n\n8 Universal LCMS-based assay platform, refmAb-Q nSMOL, for monitoring monoclonal antibody therapeutics using one reference antibody, Noriko Iawmoto, Yoshinobu Koguchi, Kotoko Yokoyama, Akinobu Hamada, Atsushi Yonezawa, Brian Piening, Eric Tran, Bernard Fox, William Redmond, and Takashi Shimada\n\nProteogenomic Characterization of Head and Neck Squamous Cell Cancer Immunopeptidomes to Detect Non Canonical Protein Targets for Cancer Immunotherapy., N Iwamoto, Richard Bryan Bell, Carlo Bifulco, Walter Urba, Rom Leidner, Brian D. Piening, Bernard A Fox, and See full author list in comments\n\nLink\n\nA rapid and universal liquid chromatograph-mass spectrometry-based platform, refmAb-Q nSMOL, for monitoring monoclonal antibody therapeutics., Noriko Iwamoto, Yoshinobu Koguchi, Kotoko Yokoyama, Akinobu Hamada, Atsushi Yonezawa, Brian D Piening, Eric Tran, Bernard A Fox, William L Redmond, and Takashi Shimada\n\nMid-pregnancy immune dysregulation and its association with maternal metabolic and genetic factors in those with preterm birth: Insights using artificial intelligence., L Jelliffe-Pawlowski, Brian D. Piening, and See full list of authors in comments\n\nLink\n\nInterim results of an ongoing phase 1/2a study of HPN328, a tri-specific, half-life extended, DLL3-targeting, T-cell engager, in patients with small cell lung cancer and other neuroendocrine cancers., Melissa Lynne Johnson, Rachel E Sanborn, and See full list of authors in comments\n\nLink\n\nEx vivo analysis of radiation effects on tumor infiltrating immune cells using tumor explants, Aanchal Preet Kaur, Gwen Kramer, Marka R. Crittenden, and Michael J. Gough\n\nLink\n\nNeoadjuvant Chemotherapy, Excision, and Observation for Early Rectal Cancer: The Phase II NEO Trial (CCTG CO.28) Primary End Point Results., Hagen F Kennecke, Chris J O'Callaghan, Jonathan M Loree, Hussein Moloo, Rebecca Auer, Derek J Jonker, Manoj Raval, Reilly Musselman, Grace Ma, Antonio Caycedo-Marulanda, Vlad V Simianu, Sunil Patel, Lacey D Pitre, Ramzi Helewa, Vallerie L Gordon, Katerina Neumann, Halla Nimeiri, Max Sherry, Dongsheng Tu, and Carl J Brown\n\nO006/#1066 Randomized trial of pelvic radiation with and without concurrent cisplatin in patients with a pelvic only recurrence of endometrial cancer, Ann Klopp, Christopher Darus, and See all authors in comments\n\nLink\n\nA Novel Class of On-Treatment Cancer Immunotherapy Biomarker: Trough Levels of Antibody Therapeutics in Peripheral Blood., Yoshinobu Koguchi and William L Redmond\n\nLink"
    }
}